Board of Trustees of The Leland Stanford Junior University’s Contineum Therapeutics CTNM Stock Holding History

Board of Trustees of The Leland Stanford Junior University’s Portfolio CTNM Stock Details CTNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-38,869	Closed	-$744K	–	27
2024 Q3	$744K	Hold	38,869	–	–	0.06%	15
2024 Q2	$684K	Buy	+38,869	New	+$626K	0.05%	16

Other funds holding CTNM

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

RTM

Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return

Board of Trustees of The Leland Stanford Junior University's CTNM Position: Q4 2024 in Review

Board of Trustees of The Leland Stanford Junior University sold out of Contineum Therapeutics (CTNM) in Q4 2024, closing a stake of 38,869 shares — an estimated $744K sold.

Board of Trustees of The Leland Stanford Junior University first reported a position in CTNM in Q2 2024 and held it in 2 quarters. The position peaked at $744K in Q3 2024. 62 funds tracked by Wall St. Rank hold CTNM as of Q4 2024.

Board of Trustees of The Leland Stanford Junior University reported no remaining Contineum Therapeutics position as of Q4 2024 after selling out during the quarter.
Board of Trustees of The Leland Stanford Junior University sold 38,869 Contineum Therapeutics shares in Q4 2024, an estimated $744K.
Board of Trustees of The Leland Stanford Junior University first reported a position in Contineum Therapeutics in Q2 2024 and held it in 2 quarters.
Board of Trustees of The Leland Stanford Junior University's Contineum Therapeutics position peaked at $744K in Q3 2024.
62 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q4 2024.

Based on Board of Trustees of The Leland Stanford Junior University's 13F filing for Q4 2024, filed 13 Feb 2025.